In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Edgewise Therapeutics Inc (NASDAQ: EWTX) closed at $14.35 down -2.05% from its previous closing price of $14.65. In other words, the price has decreased by -$2.05 from its previous closing price. On the day, 0.67 million shares were traded. EWTX stock price reached its highest trading level at $14.7 during the session, while it also had its lowest trading level at $14.13.
Ratios:
For a deeper understanding of Edgewise Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.87 and its Current Ratio is at 28.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 30, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $46.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $42. On April 30, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $41.Guggenheim initiated its Buy rating on April 30, 2025, with a $41 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 26 ’25 when Russell Alan J sold 100,000 shares for $14.60 per share. The transaction valued at 1,459,760 led to the insider holds 23,400 shares of the business.
ALAN J RUSSELL bought 100,000 shares of EWTX for $1,459,760 on Aug 26 ’25. On Aug 12 ’25, another insider, MOORE JOHN R, who serves as the General Counsel of the company, sold 2,098 shares for $13.39 each. As a result, the insider received 28,097 and left with 10,214 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EWTX now has a Market Capitalization of 1511715200 and an Enterprise Value of 922089920.
Stock Price History:
The Beta on a monthly basis for EWTX is 0.27, which has changed by -0.19742727 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, EWTX has reached a high of $38.12, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is 3.89%, while the 200-Day Moving Average is calculated to be -30.82%.
Shares Statistics:
For the past three months, EWTX has traded an average of 776.48K shares per day and 799330 over the past ten days. A total of 105.34M shares are outstanding, with a floating share count of 74.56M. Insiders hold about 29.22% of the company’s shares, while institutions hold 84.74% stake in the company. Shares short for EWTX as of 1755216000 were 10215170 with a Short Ratio of 13.16, compared to 1752537600 on 11074084. Therefore, it implies a Short% of Shares Outstanding of 10215170 and a Short% of Float of 11.3800004.
Earnings Estimates
The performance of Edgewise Therapeutics Inc (EWTX) in the stock market is under the watchful eye of 12.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.36 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.56 and -$1.67 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.93, with 11.0 analysts recommending between -$1.44 and -$2.35.
